Galectin Therapeutics
Pharmaceutical Manufacturing • 
Berkeley Lake, Georgia, United States • 21-50 Employees
Company overview
| Headquarters | 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US |
| Phone number | +16786203186 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Founded | 2000 |
| Employees | 21-50 |
| Socials |
Key Contacts at Galectin Therapeutics
Harold Shlevin
Director Board Of Directors
Sharisse Brutto
Senior Director Project Management
Michael Inkmann
Senior Director, Clinical Data Management And Programming
Jessica Kopaczewski
Senior Director Of Clinical Operations
Seth Zuckerman
Sr. Director, Biostatistics
Fahri Kaya
Co-Owner
Long Vũ Đại
Ceo
Zastawny Tomasz
Clinical Projects Director
David Platt
Owner
Galectin Therapeutics Email Formats
Galectin Therapeutics uses 2 email formats. The most common is {last name} (e.g., doe@galectintherapeutics.com), used 88.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{last name} | doe@galectintherapeutics.com | 88.2% |
{first name}{last name} | johndoe@galectintherapeutics.com | 11.8% |
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.
Galectin Therapeutics revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $25,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,200,000 |
| Total funding | $80,000,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Galectin Therapeutics has 17 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Galectin Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Galectin Therapeutics Tech Stack
Discover the technologies and tools that power Galectin Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Performance
JavaScript libraries
Security
Security
Form builders
JavaScript libraries
RUM
JavaScript libraries
CMS
JavaScript libraries
JavaScript libraries
JavaScript libraries
Denmark
United Kingdom
France
India
Switzerland
Finland
NetherlandsFrequently asked questions
4.8
40,000 users
